神威药业(02877.HK) 公布,截至2025年3月31日止三个月管理账目内营业额达7.61亿元人民币(下同),按年减少31.9%,
当中,注射液产品的营业额减少35.5%至2.62亿元;软胶囊产品的营业额减少52.9%至0.81亿元;颗粒剂产品的营业额减少41.2%至1.17亿元;中药配方颗粒产品的营业额减少13.8%至2.44亿元;及其他剂型产品的营业额减少1.7%至0.57亿元。 (ha/w)(港股报价延迟最少十五分钟。沽空资料截至 2025-05-08 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.